**Vaccine Impact Modelling Consortium – Publication Guidance**

This document provides a step-by-step guide to publishing papers and other outputs based on modellers’ work within the Vaccine Impact Modelling Consortium.

**Sensitivities around publications**

All VIMC funders – the Bill & Melinda Gates Foundation (BMGF), Gavi, and the Wellcome Trust – support open access to research outputs and therefore encourage publication of results from the Consortium. This is also a requirement of BMGF and Wellcome grants.

However, Gavi is a donor-funded public-private partnership, with a key part of its strategy being market-shaping activities. This includes negotiating with vaccine manufacturers. Forecasts of vaccine dose volumes and introduction dates form a key part of its negotiating position. Thus, there are circumstances when public release of such forecasts might weaken Gavi’s position and negatively affect negotiations. Furthermore, the vaccine impact estimates provided by the Consortium are used by Gavi for fundraising and advocacy purposes, and changes in estimates that arise – for instance due to model updates – need to be communicated with care. Key outputs that are particularly sensitive include impact estimates aggregated across all Gavi-supported countries (either for one disease or multiple diseases), as such estimates may be directly comparable with those communicated by Gavi. A list of Gavi countries is provided at the end of this document. The Secretariat will endeavour to keep modellers informed of times and issues that are particularly sensitive.

**Publication process** (see flowchart below)

This sensitivity means that all publications which (a) use confidential data supplied by Gavi through the Consortium or (b) contain estimates uploaded to Montagu must be shared with the Secretariat and approved by Gavi prior to submission. The Secretariat will share submitted publications with Gavi, which will review such submissions in at most 30 days. In most cases, it is anticipated that review will take around two weeks and will result in approval to submit, but Gavi reserves the right to delay publication by up to 60 days. In the case of (a), Gavi also reserves the right to request modifications.

In addition, Gavi requests that (c) all other publications related to Consortium work should be shared with the Secretariat at the same time as submission for publication. The Secretariat will share papers with Gavi for information only.

The publication process applies to all types of publications, including peer-reviewed journal articles, published reports, and so on.

**Confidential data supplied by Gavi**

Gavi’s confidential data is any data that Gavi has provided to the Consortium which is not in the public domain. This consists primarily of vaccine demand forecasts (often known as the strategic demand forecast (SDF), or operational forecast (OP)). Concerns also extend to cases where the SDF or OP data are not published themselves, but where relevant features (such as vaccine introduction dates) could be reasonably imputed from a publication.

**Open Access**

Open Access publishing refers to scholarly research that is freely available, accessible, and reusable. No paywalls or subscriptions are required. This approach has support from many in the academic and research communities, including key funders, publishers, libraries, and universities.

**Funding for open access publication charges**

Both the Bill & Melinda Gates Foundation and the Wellcome Trust provide funding for open access publication charges, for publications in compliant journals. Please use this [Journal Checker Tool](https://journalcheckertool.org/) to check your publication is compliant. See the [BMGF open access policy](https://openaccess.gatesfoundation.org/) and [Wellcome Trust open access guidance](https://wellcome.org/grant-funding/guidance/open-access-guidance) for more details.

**Manuscript Submissions and Publications**

Please see the [Grantee Guide](https://www.dropbox.com/s/24ugtdxvueiu3ii/Grantee_Guide_BMGF_Open_Access_Policy_v7.pdf?dl=0) steps 1-5 for more information about navigating the publishing process. Our BMGF grant ID (or Investment ID) for VIMC 2.0 is INV-034281; our Wellcome grant ID is 226727\_Z\_22\_Z.

If you have questions about your manuscript submission, its status, licenses, or the editorial process, check directly with the journal or publisher. If you have any queries or questions relating to the publication process, please contact [vimc@imperial.ac.uk](mailto:vimc@imperial.ac.uk).

**Invoicing and Payment of Publisher Fees**

All invoice payments will be managed by [openaccess@gatesfoundation.org](mailto:openaccess@gatesfoundation.org). Invoices should be addressed to BMGF at:

To: Bill & Melinda Gates Foundation c/o Open Access

PO Box 23350

Seattle WA 98102-0650

UNITED STATES

Invoices must also include:

* BMGF Grant Number INV-034281 (VIMC 2.0) previously, (OPP1157270 / INV-009125).
* Article DOI
* Indication that the article license is CC BY
* Indication that the journal is Gold or a Transformative Journal

\*If the journal is hybrid, fees will be paid for submissions prior to January 1st, 2021.  Indicate the submission date as needed.

Email your invoice to: [openaccess@gatesfoundation.org](mailto:openaccess@gatesfoundation.org), cc’d to [vimc@imperial.ac.uk](mailto:vimc@imperial.ac.uk).

[openaccess@gatesfoundation.org](mailto:openaccess@gatesfoundation.org) is available to answer your questions, including queries about data sharing, policy compliance, and payment of publishing fees.

**Conference abstracts and presentations**

Conference abstracts must be shared with the Secretariat two weeks before submission if they (a) use confidential data supplied by Gavi through the Consortium, or (b) contain estimates uploaded to Montagu. Other conference abstracts related to Consortium work should be shared with the Secretariat at the same time as submission, and the Secretariat will share these with Gavi for information only.

In terms of slides and posters that you plan to present at conferences, where these (a) use confidential data supplied by Gavi through the Consortium or (b) contain estimates uploaded to Montagu, you should share a completed draft of your slides or poster with the Secretariat two weeks in advance of presenting this. The numbers contained in this version should be the final numbers that you present on the day. The Secretariat will share these with Gavi, which will review them. Any other slides and posters related to Consortium work should be shared with the Secretariat at or just after presentation; the Secretariat will share these with Gavi for information only.

**Media interviews**

Please contact the Secretariat as early as possible if you plan to give any media interviews relating to Consortium work.

**Press releases**

Any press releases relating to Consortium work should be sent to the Secretariat at least three weeks in advance, in order to allow all parties a reasonable chance to comment. The Secretariat will share the press release with all funders and advise you if this can go ahead.

**Acknowledgements and use of funders’ names**

Please use the following acknowledgement in all publications:

*This work was carried out as part of the Vaccine Impact Modelling Consortium (www.vaccineimpact.org), but the views expressed are those of the authors and not necessarily those of the Consortium or its funders. The funders were given the opportunity to review this paper prior to publication, but the final decision on the content of the publication was taken by the authors.*

*This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation, via the Vaccine Impact Modelling Consortium [Grant Number INV-034281], previously (OPP1157270 / INV-009125). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.*

Gavi must give prior written consent to any materials mentioning its name. BMGF requires two weeks to comment on any materials mentioning its name. As sub-grantees of BMGF funding, you must not create the impression that you are a direct recipient of BMGF funds.

For more information about Creative Commons licences, see ‘Funding for open access publication charges’ above.

**Logo use**

We encourage you to include the Consortium logo in any relevant publications, presentations and other materials. Please contact [vimc@imperial.ac.uk](mailto:vimc@imperial.ac.uk) to request this. You should not include the BMGF or Gavi logos without prior permission from the funders.

**Contacting the Consortium Secretariat**

For all enquiries about publications or communications, please contact [vimc@imperial.ac.uk](mailto:vimc@imperial.ac.uk).

**Summary of publication types**

|  |  |  |  |
| --- | --- | --- | --- |
| **Type** | **Criteria** | **Gavi approval required before submission?** | **Potential requests that Gavi may make** |
| (a) | Publications which use confidential data\* supplied by Gavi through the Consortium | Yes | Modifications to the publication or delays to the publication date (by up to 60 days) |
| (b) | Publications which contain estimates uploaded to Montagu | Yes | Delay to publication date (by up to 60 days) |
| (c) | All other publications related to Consortium work | No | None |

\* see explanation of ‘confidential data’ on page 1

**Flowchart for publishing journal articles related to Consortium work**

Use the [Journal Checker Tool](https://journalcheckertool.org/) to ensure the journal meets open access requirements

**UK academics only:** Once your article is accepted, in order to comply with HEFCE/REF requirements, you may also need to register this in your university’s open access repository.

**START HERE:** You want to submit an article related to Consortium work for publication.

Your article is accepted.

Notify Secretariat as soon as possible after acceptance.

Email your completed draft publication and publication form to the Secretariat at least two weeks before submission. Submission can only proceed after Gavi approval.

**Yes**

Gavi will need to check the publication carefully.

The Secretariat will acknowledge receipt and will share your publication with all funders as a courtesy only.

Type (c)

Types (a) and (b)

**No**

Email your completed draft publication and form to the Secretariat at the time of submission.

Submit your publication using the Grantee Guide Steps 1-5

Gavi confirms submission can proceed.

You liaise with Gavi and revise the publication

Does the publication contain confidential Gavi data, or estimates uploaded to Montagu?

Gavi notifies you of any concerns within 30 days. Gavi may request a publication delay of up to 60 days.

The Secretariat will acknowledge receipt and share your publication with Gavi.

**Contact the VIMC secretariat:** [vimc@imperial.ac.uk](mailto:vimc@imperial.ac.uk)

**VIMC publication form – please use this when sharing draft publications with the Secretariat:**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Publication title: | | | | | | |
|  | | | | | | |
| Authors: | | | | | | |
|  | | | | | | |
| Corresponding author email address: | | |  |  |  |  |
| Does the publication use Gavi confidential data?  (e.g. SDF / OP data) | | | Yes | 🞏 | No | 🞏 |
| If yes, please state which data are used (including version number) and the years covered: | | | | | | |
|  | | | | | | |
| Which diseases/antigens does the publication relate to? Please tick all that apply: | | | | | | |
| Hepatitis B | 🞏 | Meningitis A | | | 🞏 | |
| Hib | 🞏 | Pneumococcal disease | | | 🞏 | |
| HPV | 🞏 | Rotavirus | | | 🞏 | |
| Japanese encephalitis | 🞏 | Rubella | | | 🞏 | |
| Measles | 🞏 | Yellow fever | | | 🞏 | |
| Other (please state): |  | | | | | |
| Which countries/regions does the publication relate to? | | | | | | |
| Which years does outputs pertain to? | | | | | | |
|  | | | | | | |
| Can aggregated estimates for the Gavi 73 countries be obtained from the reported results? For Japanese encephalitis, Meningitis A and Yellow Fever, this refers only to the subset of the Gavi 73 countries that are eligible for Gavi funding for those vaccines. Lists of these countries are shown below. | | | | | | |
|  | | | | | | |
| Abstract: | | | | | | |
|  | | | | | | |

**List of 73 Gavi-supported countries**

From Lee et al. (2013) *The estimated mortality impact of vaccinations forecast to be administered during 2011–2020 in 73 countries supported by the GAVI Alliance*

|  |  |
| --- | --- |
| Afghanistan | Lesotho |
| Angola | Liberia |
| Armenia | Madagascar |
| Azerbaijan | Malawi |
| Bangladesh | Mali |
| Benin | Mauritania |
| Bhutan | Moldova |
| Bolivia | Mongolia |
| Burkina Faso | Mozambique |
| Burundi | Myanmar |
| Cambodia | Nepal |
| Cameroon | Nicaragua |
| Central African Republic | Niger |
| Chad | Nigeria |
| Comoros | Pakistan |
| Congo, DR | Papua New Guinea |
| Congo, Republic | Rwanda |
| Côte d’Ivoire | São Tomé and Principe |
| Cuba | Senegal |
| Djibouti | Sierra Leone |
| Eritrea | Solomon Islands |
| Ethiopia | Somalia |
| Gambia | Sri Lanka |
| Georgia | South Sudan |
| Ghana | Sudan, Republic of |
| Guinea | Tajikistan |
| Guinea-Bissau | Tanzania |
| Guyana | Timor-Leste |
| Haiti | Togo |
| Honduras | Uganda |
| India | Ukraine |
| Indonesia | Uzbekistan |
| Kenya | Vietnam |
| Kiribati | Yemen |
| Korea, DR | Zambia |
| Kyrgyz Republic | Zimbabwe |
| Lao PDR |  |

**List of 32 countries eligible for Gavi funding for yellow fever (YF) vaccine**

|  |  |
| --- | --- |
| Angola | Kenya |
| Benin | Liberia |
| Burkina Faso | Mali |
| Burundi | Mauritania |
| Cameroon | Niger |
| Central African Republic | Nigeria |
| Chad | Rwanda |
| Congo, DR | Senegal |
| Congo, Republic | Sierra Leone |
| Côte d'Ivoire | Somalia |
| Eritrea | South Sudan |
| Ethiopia | Sudan, Republic of |
| Gambia | Tanzania |
| Ghana | Togo |
| Guinea | Uganda |
| Guinea-Bissau | Zambia |

**List of 26 countries eligible for Gavi funding for meningitis A (Men A) vaccine**

|  |  |
| --- | --- |
| Benin | Guinea-Bissau |
| Burkina Faso | Kenya |
| Burundi | Mali |
| Cameroon | Mauritania |
| Central African Republic | Niger |
| Chad | Nigeria |
| Congo, DR | Rwanda |
| Côte d'Ivoire | Senegal |
| Eritrea | South Sudan |
| Ethiopia | Sudan, Republic of |
| Gambia | Tanzania |
| Ghana | Togo |
| Guinea | Uganda |

**List of 14 countries eligible for Gavi funding for Japanese encephalitis (JE) vaccine**

|  |  |
| --- | --- |
| Bangladesh | Myanmar |
| Bhutan | Nepal |
| Cambodia | Pakistan |
| India | Papua New Guinea |
| Indonesia | Sri Lanka |
| Korea, DR | Timor-Leste |
| Lao PDR | Vietnam |